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Abstract
Background: Recent studies highlight a negative association between total bilirubin concentrations and albuminuria
in patients with type 2 diabetes mellitus. Our study evaluated the relationship between bilirubin concentrations and
the prevalence of diabetic nephropathy (DN) in Chinese patients with type 1 diabetes mellitus (T1DM).
Methods: A total of 258 patients with T1DM were recruited and bilirubin concentrations were compared between
patients with or without diabetic nephropathy. Multiple stepwise regression analysis was used to examine the
relationship between bilirubin concentrations and 24 h urinary microalbumin. Binary logistic regression analysis
was performed to assess independent risk factors for diabetic nephropathy. Participants were divided into four groups
according to the quartile of total bilirubin concentrations (Q1, 0.20–0.60; Q2, 0.60–0.80; Q3, 0.80–1.00; Q4, 1.00–1.90 mg/dL)
and the chi-square test was used to compare the prevalence of DN in patients with T1DM.
Results: The median bilirubin level was 0.56 (interquartile: 0.43–0.68 mg/dL) in the DN group, significantly
lower than in the non-DN group (0.70 [interquartile: 0.58–0.89 mg/dL], P < 0.001). Spearman’s correlational analysis
showed bilirubin concentrations were inversely correlated with 24 h urinary microalbumin (r = -0.13, P < 0.05) and
multiple stepwise regression analysis showed bilirubin concentrations were independently associated with 24 h
urinary microalbumin. In logistic regression analysis, bilirubin concentrations were significantly inversely associated
with nephropathy. In addition, in stratified analysis, from the first to the fourth quartile group, increased bilirubin
concentrations were associated with decreased prevalence of DN from 21.90% to 2.00%.
Conclusion: High bilirubin concentrations are independently and negatively associated with albuminuria and the
prevalence of DN in patients with T1DM.
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Background
Diabetic nephropathy (DN) is the most common cause
of end-stage renal disease worldwide, which remains a
major cause of morbidity and mortality in patients with
T1DM [1]. Oxidative stress may be a common pathway
linking diverse, seemingly distinct, potential mechanisms
underlying the pathogenesis of complications in
diabetes, including nephropathy [2]. Bilirubin is the end
product of haem catabolism and it acts as a powerful
biological antioxidant [3, 4]. A study on Gilbert
syndrome (GS) reported that the prevalence of ischemic
heart disease (IHD) was 2% in GS patients (who are
characterised by high bilirubin concentrations) com-
pared to 12.1% in the general population, indicating that
chronic hyperbilirubinemia prevents the development of
IHD by increasing the antioxidant capacity of serum [5].
In a recent study that used the deoxycorticosterone acet-
ate (DOCA)-salt model of hypertension in Heine
oxygenase (HO)-1-/- and HO-1+/+ mice, systolic arterial
pressure was significantly elevated in HO-1-/- mice
treated with DOCA salt but not in HO-1+/+ mice; in
addition, DOCA-salt impaired vasorelaxation was noted
in wild-type rats but not in hyperbilirubinemic rats [6].
These results suggest that the HO-1 isozyme and the
product bilirubin may have protective effects on vascular
disease. This finding has also been confirmed in a model
of balloon injury [7]. In addition, diabetic hyperbilirubi-
nemic Gunn j/j rats excrete significantly less urinary
albumin than diabetic non-hyperbilirubinemic Gunn j/+
rats and administration of biliverdin (5 mg/kg) protects
against both albuminuria and renal mesangial expansion
in db/db mice [8]. These findings suggest that bilirubin
and biliverdin may protect against DN. A population-
based study showed that high bilirubin concentrations in
serum are associated with reduced risk of DN [9].
Furthermore, several longitudinal studies on healthy sub-
jects and type 2 diabetes mellitus (T2DM) also demon-
strated that low serum bilirubin concentration could be a
novel risk factor for the development of albuminuria in
patients with type 2 diabetes [10, 11]. However, renal
disease remains a major cause of morbidity and mortality
in patients with T1DM and the association between biliru-
bin concentrations in serum and the prevalence of
diabetic nephropathy in patients with T1DM has not yet
been studied. Therefore, in the present study, we evalu-
ated the association between bilirubin concentrations in
serum and the prevalence of DN, and we hypothesized
that bilirubin concentrations may inversely associate with
the prevalence of DN in Chinese patients with T1DM.
Methods
Study population
This was a cross-sectional, population-based study
involving 258 patients with T1DM. Participants were
hospitalised patients who presented at the Department
of Endocrinology and Metabolism, Shanghai Jiaotong
University Affiliated Sixth People’s Hospital between
January 2008 and January 2013. T1DM was defined as
anti-glutamate decarboxylase (GAD) antibody level ≥ 1.5
U/mL and injecting insulin at least three times daily or
using an insulin pump, and DN were diagnosed accord-
ing to KDOQI Clinical Practice Guidelines and Clinical
Practice Recommendations for Diabetes and Chronic
Kidney Disease for 2007 [12]. Hypertension was diag-
nosed if the patient had a blood pressure greater than
140/90 mmHg or used anti-hypertensive drugs. Subjects
were excluded for the following reasons: absence of data
(bilirubin, haemoglobin A1c [HbA1c]), abnormal thyroid
function (hyperthyroidism or hypothyroidism), elevated
serum levels of creatinine (>124 μmol/L), serum bilirubin
concentrations > 2.0 mg/dL, and T2DM or specific
diabetes. In addition, patients were excluded if they had
confounding hepatobiliary or haemolytic disease, hepatitis
B or C, alcoholic liver disease, gallstones, cirrhosis, IgA
nephropathy, or urinary tract infections.
Clinical and laboratory measurements
The clinical parameters investigated included age,
height, weight, duration of diabetes, systolic blood pres-
sure (SBP), diastolic blood pressure (DBP), waist circum-
ference (WC), hip circumference, and waist-to-hip ratio
(WHR). Biochemical variables were analysed after an
overnight fast of at least 10 h and included fasting
plasma glucose (FPG), 2 h postprandial glucose (2hPG),
glycated haemoglobin A1c (HbA1c), glycated albumin
(GA), C-reactive protein (CRP), 30-min postprandial
venous C peptide, 120-min postprandial venous C
peptide, albumin, aspartate aminotransferase (AST),
alamine aminstransferase (ALT), gamma glutamytrans-
ferase (γ-GT), total cholesterol (TC), triglyceride level
(TG), low-density lipoprotein cholesterol (LDL-C), high-
density lipoprotein cholesterol (HDL-C), haemoglobin
(Hb), 24 h urinary microalbumin, total GFR, uric acid,
creatinine (Cr), and total bilirubin.
Subject height was measured to the nearest 0.1 cm
with subjects not wearing shoes and weight was
measured to the nearest 0.1 kg while the subjects wore
light clothing; BMI was calculated as weight (kg) divided
by the square of the height (m). SBP and DBP were
measured after participants had rested for at least 5 min.
WC (cm) was measured midway between the costal
margin and the iliac crest at the end of a normal expir-
ation and the hip circumference was measured as the
circumference around both greater femoral trochanters.
The WHR was calculated by dividing waist by hip
circumference (cm). All biochemical determinations
were performed using the same standard laboratory
methods. After overnight fasting, blood was drawn early
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in the morning from the antecubital vein into vacuum
tubes to determine the concentrations of fasting plasma
glucose (FPG), C peptide, CRP, and concentrations of
lipid components and liver enzymes. Bilirubin concen-
trations from serum samples were determined using the
vanadate oxidation method.
Measurement of GFR using the 99mTc-diethylene
triamine pentaacetic acid (99mTc-DTPA) renal dynamic
imaging method, and 99mTc-DTPA renal dynamic
imaging (modified Gate’s method) was measured by
Millennium TMMPR SPECT from General Electric
Medical System [13]. Urine albumin excretions were
evaluated by calculating total amounts of 24 h urinary
microalbumin. The stage of albuminuria was defined as
normal if no more than 30 mg/24 h, microalbuminuria if
24 h urinary microalbumin was 30–299 mg/24 h, and
macroalbuminuria if 24 h urinary microalbumin was
equal to or higher than 300 mg/24 h [12].
Statistical analysis
Data are expressed as the means + standard deviation
(SD) for a normal distribution of variables or as the
median (interquartile range) for a skewed distribution of
variables. For continuous data with a normal distribution
and a skewed distribution between DN and non-DN
patients, unpaired Student’s t-tests and nonparametric
tests, respectively, were used for statistical analyses.
Categorical variables were compared using a chi-square
test. Spearman’s correlational analysis between 24 h
urinary microalbumin, and other variables was per-
formed. Multiple stepwise regression analysis was
performed to assess the relationship between bilirubin
concentrations and 24 h urinary microalbumin. Binary
logistic regression analysis was performed to assess inde-
pendent risk factors for diabetic nephropathy. Partici-
pants were divided into four groups according to the
quartile of total bilirubin concentrations and the chi-
square test was used to compare the prevalence of DN
in patients with T1DM. The first quartile was
0.20–0.60 mg/dL, second quartile was 0.60–0.80 mg/dL,
third quartile was 0.80–1.00 mg/dL, and fourth quartile
was 1.00–1.90 mg/dL. All statistical analyses were
performed using SPSS version 17.0 for Windows (SPSS,
Chicago, IL, USA). A P-value less than 0.05 was consid-
ered to indicate statistical significance.
Results
Patient demographics and laboratory data
This study included 33 DN and 225 non-DN patients
with T1DM. The general and biochemical characteristics
of the DN patients (16 males and 17 females) and
non-DN patients (111 males and 114 females) are shown
in Table 1. The prevalence of patients with diabetic
nephropathy, without nephropathy, were 12.8% (n = 33),
87.2% (n = 225), respectively. Of 33 patients with diabetic
nephropathy, 20 were with microalbuminuria and 13
were with macroalbuminuria. The median age was
54 years (34.50–66 years) in DN subjects and 49 years
(31–60 years) in non-DN patients. Median bilirubin
concentrations were 0.56 mg/dL (0.43–0.68 mg/dL) in
the DN group and 0.70 mg/dL (0.58–0.89 mg/dL) in
non-DN patients (P < 0.01), a significant difference. 24 h
urinary microalbumin level was significantly higher in
the DN group than the non-DN group (196.67 mg vs.
7.01 mg, P < 0.01) and the same trend was observed with
the duration of diabetes, SBP, WHR, uric acid, creatinine
levels (P < 0.01), whereas albumin, haemoglobin, and
total GFR levels were lower in the DN group (P < 0.05).
Bilirubin concentrations in serum are independently and
negatively associated with 24 h urinary microalbumin
Previous studies have shown that microalbuminuria can
indicate the progression of DN in patients with T1DM
[14, 15]. To investigate the risk factors associated with
microalbuminuria, we performed Spearman’s correlation
analysis between bilirubin concentrations and other
biochemical characteristics. As expected, 24 h urinary
microalbumin was negatively correlated with bilirubin con-
centrations (r = -0.13, P < 0.05), HDL-C (r = -0.16, P = 0.01),
and total GFR (r = -0.20, P < 0.001) and positively correlated
with duration of diabetes, BMI, SBP, WHR, CRP, uric acid,
Cr, TG levels (all P < 0.001). These results are presented
in Table 2. To determine whether bilirubin concentra-
tions were independently correlated with 24 h urinary
microalbumin, we performed multiple stepwise regres-
sion analysis. Cr (β = 0.45, P < 0.001), total bilirubin
(β = -0.19, P < 0.001), SBP (β = 0.15, P = 0.005) levels
were independently related to 24 h urinary microalbu-
min. This result is shown in Table 3.
Bilirubin concentrations in serum are independently
associated with diabetic nephropathy
The significant 24 h urinary microalbumin-related
findings prompted a binary logistic regression analysis to
identify factors that were independently correlated with
DN. When DN was set as the dependent variable and
bilirubin concentrations, duration of diabetes, BMI, SBP,
DBP, WHR, HbA1c, GA, CRP, Fasting C peptide, FPG,
CRP, HDL-C, TG, TC, LDL-C, Albumin, Haemoglobin
were set as covariates, bilirubin concentrations were
identified as an independent protective factor for DN
(OR = 0.05, 95% confidence interval [CI]: 0.01–0.66),
while duration of diabetes (OR =1.15, 95% CI:
1.07–1.22) and SBP (OR = 1.05, 95% CI: 1.02–1.08) were
identified as independent risk factors for DN (all P < 0.01,
Table 4).
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Bilirubin concentrations in serum are negatively
associated with the prevalence of DN in patients with
T1DM
The prevalence of DN in patients with T1DM for each
quartile of bilirubin concentrations is illustrated in
Table 5. The first quartile group had the highest preva-
lence of DN (21.90%) among the four quartiles. From
the second to the fourth quartile group, the prevalence
of DN decreased from 17.10% to 2.00% as bilirubin
concentrations increased. ORs from the third to
fourth quartile were statistically significant compared to the
first quartile using logistic regression analyses (all P < 0.05),
but not in the second quartile (P = 0.48). After adjusting for
duration of diabetes, BMI, TG, Albumin, Haemoglobin and
WHR, the ORs for the prevalence of DN decreased
significantly with the quartiles of bilirubin concentra-
tions (P for the trend = 0.04). Therefore, we deduced
that high bilirubin concentrations in serum (0.80–
1.90 mg/dL) may be a protective factor for the
development of DN in Chinese patients with T1DM.
Discussion
Several previous studies have reported that high bilirubin
concentrations in serum are negatively associated with the
Table 1 Patient demographics and laboratory data
DN (n = 33) Non-DN (n = 225) P-value
Male: Female 16:17 111:114 0.98
Age (years) 54 (34.50–66) 49 (31–60) 0.06
Duration of diabetes (years) 13.92 (5.50–20) 4.56 (1–8) <0.001**
BMI (kg/m2) 22.67 (21.85–22.75) 21.85 (17.75–33.65) 0.09
SBP (mmHg) 130 (120–140) 120 (110–125) <0.001**
DBP (mmHg) 79 (70–80) 78 (70–80) 0.81
WHR 0.87 (0.85–0.94) 0.86 (0.83–0.88) 0.01*
FPG (mmol/L) 8.24 (5.71–11.47) 7.73 (6.18–10.70) 0.48
2hPG (mmol/L) 12.74 + 6.73 14.03 + 5.57 0.23
HbA1c (mmol/mol) 79 (62–95) 79 (60–105) 0.68
GA (%) 27.50 (21.50–31) 27.50 (23–34) 0.44
CRP (mg/L) 1.01 (0.66–3.87) 0.68 (0.27–2.86) 0.25
Uric acid (mg/dL) 328 (246.50–414.5) 272 (223–316.50) <0.001**
Cr (mg/dL) 78 (60–99.50) 63 (52–74) 0.01*
Fasting C peptide (ng/mL) 0.19 (0.03–1.13) 0.29 (0.05–0.80) 0.56
30-min postprandial venous C peptide (ng/mL) 0.1 (0.03–0.96) 0.35 (0.05–1.17) 0.93
120-min postprandial venous C peptide (ng/mL) 0.08 (0.03–1.62) 0.48 (0.07–1.58) 0.64
Albumin (g/dL) 41 (37.50–43) 42.44 (40–45) <0.001**
ALT (U/L) 16 (11–24.5) 17 (12–25) 0.56
AST (U/L) 18 (15–24) 19 (15–24) 0.42
γ-GT(U/L) 18 (16–23.50) 15 (12–22) 0.73
Total Bilirubin (mg/dL) 0.56 (0.43–0.68) 0.70 (0.58–0.89) <0.001**
TC (mmol/L) 4.75 + 1.34 4.41 + 0.99 0.09
TG (mmol/L) 1.09 (0.87–1.62) 0.88 (0.70–1.17) 0.07
HDL-C (mmol/L) 1.28 (0.95–1.66) 1.27 (1.10–1.60) 0.59
LDL-C (mmol/L) 2.69 (2.18–3.36) 2.68 (2.16–3.39) 0.17
Haemoglobin (g/dL) 126 (109.50–136.5) 130 (74–171) 0.04*
24 h urinary microalbumin (mg/24 h) 196.67(49.27–1123.33) 7.01 (4.89–10.44) <0.001**
Total GFR (mL/min) 81.75 (60.35–96.03) 98.95(86.95–107.20) <0.001**
Data are expressed as the means + standard deviation (SD) for normal distribution variables or as the median (interquartile range) for skewed distribution variables
Abbreviations: DN diabetic nephropathy, T1DM type 1 diabetes mellitus, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, WHR
waist-to-hip ratio, FPG fasting plasma glucose, 2hPG 2 h postprandial glucose, HbA1c glycated haemoglobin A1c, GA glycated albumin, Cr creatinine, CRP C-reactive
protein, ALT alanine aminotransferase, AST asparatate aminotransferase, γ-GT γ-glutamyltranspeptidase, TC total cholesterol, TG triglycerides, HDL-C high--
density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, GFR glomerular filtration rate, OR odds ratio, 95% CI 95% confidence interval
*P < 0.05, **P < 0.01
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incidence of hypertension [16] and T2DM [17]. In
addition, a recent study demonstrated that bilirubin
concentrations were significantly negatively correlated
with log (UAE) in patients with type 1 diabetes [18]. We
performed a cross-sectional study to examine whether
bilirubin concentrations in serum are associated with the
prevalence of DN in patients with T1DM. We found that
bilirubin concentrations were independently and nega-
tively associated with albuminuria and the prevalence of
DN in patients with T1DM. We deduced a range of biliru-
bin concentrations (0.80–1.90 mg/dL) that may serve as
protective factors for the development of DN in Chinese
patients with T1DM and likely represent a pharmacologic-
ally attractive target for slowing the development of DN.
We found that bilirubin concentrations and HbA1c level
were not relevant (r = 0.06, P = 0.334) in 258 patients with
type 1 diabetes mellitus (33 patients with diabetic ne-
phropathy, 225 patients without diabetic nephropathy).
However, a study from Choi SW et al. evaluated the
relationship between HbA1c and bilirubin in 690 patients
with type 2 diabetes mellitus and found that bilirubin
concentrations were negatively associated with HbA1c, in-
dependent of gender, age, and other confounding factors
[19]. Because several studies have confirmed that high bili-
rubin concentrations are inversely associated with insulin
resistance [20–22], T1DM is possibly due to β-cell
destruction and leads to absolute insulin deficiency rather
than insulin resistance. Furthermore, results from
Mianowska B et al. showed that serum total bilirubin con-
centration is an independent factor inversely associated
with HbA1c level in young patients with type 1 diabetes
(type 1 diabetes duration of more than 12 months, age
from 2 to 18 years) [23], which means that in T1DM, the
results are controversial. Thus, we infer that the unsyn-
chronized results of relationship between serum bilirubin
concentration and HbA1c in patients with diabetes
mellitus were attributed to the age, duration of diabetes
mellitus and glycemic control. Therefore, we admitted
that further study should be designed to investigate the
Table 2 Correlations of 24 h urinary microalbumin with
bilirubin concentrations and other characteristics in subjects
with T1DM
24 h urinary microalbumin (unadjusted)
r P-value
Age 0.07 0.24






2hPG − 0.10 0.13
HbA1c 0.02 0.72
GA − 0.05 0.45
CRP 0.19 <0.001**
Uric acid 0.23 <0.001**
Cr 0.20 <0.001**







TC − 0.01 0.98
TG 0.24 <0.001**
HDL-C − 0.16 0.01*
LDL-C − 0.01 0.88
Albumin − 0.07 0.27
Haemoglobin − 0.03 0.65
Total bilirubin − 0.13 0.03*
Total GFR − 0.20 <0.001**
Abbreviations: T1DM type 1 diabetes mellitus, BMI body mass index, SBP
systolic blood pressure, DBP diastolic blood pressure, WHR waist-to-hip ratio,
FPG fasting plasma glucose, 2hPG 2 h postprandial glucose, HbA1c glycated
haemoglobin A1c, GA glycated albumin, Cr creatinine, CRP C-reactive protein,
TC total cholesterol, TG triglycerides, HDL-C high-density lipoprotein cholesterol,
LDL-C low-density lipoprotein cholesterol, GFR glomerular filtration rate
*P < 0.05, **P < 0.01
Table 3 Multiple stepwise regression analysis showing the
variables independently associated with 24 h urinary microalbumin
Independent variable Standardised β t P-value
Cr 0.45 8.34 <0.001**
Total bilirubin −0.19 −3.65 <0.001**
SBP 0.15 2.85 0.005**
The original model included the duration of diabetes, BMI, SBP, WHR, Cr, uric
acid, CRP, TG, total bilirubin, GFR
Abbreviations: BMI body mass index, SBP systolic blood pressure, WHR waist-to-hip
ratio, Cr creatinine, CRP C-reactive protein, TG triglycerides, GFR glomerular
filtration rate
**P < 0.01
Table 4 Independent risk factors associated with the diabetic
nephropathy in patients with type 1 diabetes
B Wald P-value Exp (B) 95% CI
Duration of diabetes (years) 0.14 17.38 <0.001** 1.15 1.07–1.22
SBP (mmHg) 0.05 8.93 <0.001** 1.05 1.02–1.08
Total bilirubin (mg/d) −3.01 5.17 0.002** 0.05 0.01–0.66
Variables of the original model included duration of diabetes, BMI, SBP, DBP,
WHR, HbA1c, GA, CRP, Fasting C peptide, FPG, CRP, HDL-C, TG, TC, LDL-C, Albumin,
Haemoglobin and total bilirubin. Only significant variables are presented
Abbreviations: BMI body mass index, SBP systolic blood pressure, WHR waist-to-hip
ratio, FPG fasting plasma glucose, HbA1c glycated haemoglobin A1c, GA glycated
albumin, CRP C-reactive protein, TC total cholesterol, TG triglycerides, HDL-C high--
density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, CRP C-
reactive protein, HDL-C high-density lipoprotein cholesterol, TG triglycerides, 95% CI
95% confidence interval
**P < 0.01
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relationship between serum bilirubin concentration and
HbA1c in type 1 diabetes mellitus.
Although several studies have been performed, the
exact mechanism underlying the negative association
between high bilirubin concentrations and the progres-
sion of T1DM remains unknown. A previous study dem-
onstrated that diabetic hyperbilirubinemic Gunn j/j rats
with high concentrations of unconjugated bilirubin in
plasma excreted significantly less urinary albumin than
diabetic non-hyperbilirubinemic Gunn j/+ rats, and that
administration of biliverdin (5 mg/kg) protected against
both albuminuria and renal mesangial expansion in db/db
mice. The same authors subsequently discovered that
treatment with bilirubin and biliverdin completely inhib-
ited oxidative stress-induced increased expression of
NOX4 mRNA and protein levels of cultured vascular
endothelial and mesangial cells [8]. These findings suggest
that bilirubin and biliverdin significantly inhibit NADPH-
dependent superoxide production. A study using an
isolated, perfused rat kidney model demonstrated that
micromolar dose administration of exogenous bilirubin
resulted in significantly improved renal vascular resist-
ance, urine output, glomerular filtration rate, tubular
function, and mitochondrial integrity after ischemia-
reperfusion injury (IRI) and showed that bilirubin
pretreatment may have future clinical applications,
particularly in IRI after organ transplantation [24].
Furthermore, studies on diabetic rats have shown that
exogenously administered CO or bilirubin can protect
endothelial cells from oxidative stress-mediated injury
[25]. A study on hyperbilirubinemia caused by atazanavir
treatment in 16 subjects with T2DM indicated that hyper-
bilirubinemia is associated with a significant improvement
in endothelial function [26]. Considering that oxidative
stress, described as increased levels of reactive oxygen
species, may be a common pathway linking diverse mech-
anisms underlying the pathogenesis of complications in
diabetes [2] and that hyperglycemia-induced increases in
blood pressure and changes in endothelial cells are
reversed by antioxidants [27, 28], high concentrations of
bilirubin in serum may potentially serve as protective
factors against the development of DN through their
antioxidative properties.
This study had several limitations. First, only total
bilirubin concentrations in serum were measured,
without distinguishing between conjugated versus
unconjugated bilirubin. Second, this was a single-center,
cross-sectional study, which prevented us from drawing
conclusions regarding the temporal nature of the
observed association between bilirubin concentrations
and the prevalence of DN in Chinese patients with
T1DM. Third, the study population consisted of Chinese
males and females and whether our findings apply to
other ethnic groups remains unclear.
Conclusion
In conclusion, our study evaluated the association
between total bilirubin and albuminuria, the prevalence
of DN in Chinese patients with T1DM. Our data indi-
cate that high bilirubin concentrations in serum may be
protective factors for the development of DN.
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